Free tool
FAERS Monitor: Novolin R
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 019938 or its brand name (Novolin R, Insulin Recombinant Human). Reports on generic versions are filed under their own applications.
Reports
7,159
Serious
5,139
72% of reports
Hospitalization
2,828
Death reported
819
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,019
- drug ineffective378
- nausea376
- blood glucose decreased361
- hypoglycaemia298
- diarrhoea294
- dyspnoea276
- renal failure249
- fatigue239
- dizziness236
- fall233
- death227
- malaise226
- vomiting217
- headache204
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 87 |
| 2005 | 162 |
| 2006 | 212 |
| 2007 | 131 |
| 2008 | 201 |
| 2009 | 337 |
| 2010 | 255 |
| 2011 | 212 |
| 2012 | 249 |
| 2013 | 290 |
| 2014 | 357 |
| 2015 | 811 |
| 2016 | 553 |
| 2017 | 549 |
| 2018 | 635 |
| 2019 | 562 |
| 2020 | 297 |
| 2021 | 294 |
| 2022 | 219 |
| 2023 | 167 |
| 2024 | 195 |
| 2025 | 276 |
| 2026 | 108 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,000 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose decreasedSignal | 361 | 22.2 | 20.1 | 7,266 |
| hypoglycaemiaSignal | 298 | 18.2 | 16.2 | 4,795 |
| blood glucose increasedSignal | 1,019 | 16.0 | 15.1 | 14,336 |
| renal failureSignal | 249 | 5.5 | 4.9 | 921 |
| fallSignal | 233 | 2.1 | 1.8 | 128 |
| malaise | 226 | 1.5 | 1.3 | 40 |
| dyspnoea | 276 | 1.4 | 1.3 | 37 |
| nausea | 376 | 1.4 | 1.3 | 43 |
| dizziness | 236 | 1.4 | 1.2 | 26 |
| vomiting | 217 | 1.4 | 1.2 | 20 |
| diarrhoea | 294 | 1.3 | 1.2 | 26 |
| headache | 204 | 1.0 | 0.8 | 0 |
| fatigue | 239 | 0.9 | 0.8 | 3 |
| drug ineffective | 378 | 0.8 | 0.8 | 12 |
| death | 227 | 0.8 | 0.7 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.